Ruxolitinib has boxed warnings. What’s the evidence that it is associated with the same adverse events that appear on the boxed warnings for oral JAK inhibitors?

Featuring Alexandra Golant, MD |

Medical Director, Dermatology Faculty Practice
Associate Director, Residency Program
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

| Published January 31, 2022

View video transcript